 |
Sermorelin, also known as Growth Hormone-Releasing Hormone (GHRH) (1-29), is a synthetic peptide analog of the naturally occurring GHRH. It was developed to stimulate the production and secretion of growth hormone (GH) from the pituitary gland. Initially synthesized in the 1970s, sermorelin has since been investigated for its potential therapeutic applications in stimulating growth, improving body composition, and combating age-related decline in GH levels.
Recommended Dosage: The recommended dosage of sermorelin typically ranges from 0.1 to 0.3 milligrams (mg) per day, administered via subcutaneous injection. Treatment duration may vary depending on individual patient characteristics, treatment goals, and response to therapy. It is advisable to start with a lower dosage and titrate upwards based on clinical response and tolerability. Sermorelin therapy should be initiated and monitored under the supervision of a qualified healthcare provider familiar with its use.
